Clinical Study

A Phase III Randomized, Double Blind Trial Of Chemoembolization With Or Without Sorafenib In Unresectable Hepatocellular Carcinoma (Hcc) In Patients W

Posted Date: May 15, 2019

  • Investigator: Olugbenga Olowokure
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to see if adding the oral chemotherapy pill, sorafenib (Nexavar), to localized chemotherapy to the liver will help patients to live longer than treatment with localized chemotherapy to the liver without sorafenib. Sorafenib is currently approved by the United States Fo

Criteria:

Eligible Patients Must Have Liver Cancer (Hepatocellular Carcinoma) That Is Not Able To Be Removed B

Keywords:

E1208, Gastrointestinal Can, Gi Cancer, Hcc, Unresectable

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.